Wednesday, November 11, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Earnings callYahoo Finance· February 2, 2026

Aptiv Q4 Earnings Call Highlights

View original at finance.yahoo.com
Aptiv Q4 Earnings Call Highlights Aptiv logo 3 Stocks Powering the Future of Autonomous Driving Aptiv (NYSE:APTV) reported record fourth-quarter revenue and outlined its 2026 outlook during its Q4 2025 earnings call, highlighting continued progress in expanding beyond automotive markets and preparing for the planned Ap…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The company expects minimal supply impact in 2026, but anticipates higher semiconductor input costs that it expects to pass through to customers

    80% confidence
  • The higher tax rate is attributed to implementation of the Pillar 2 global minimum tax and the cash tax rate is expected to be about 300 basis points lower than the effective rate

    80% confidence
  • Approximately 80% of Aptiv's China new business awards in 2025 came from local OEMs

    80% confidence
  • After the debt paydown, management expects both new Aptiv and VersaGen gross leverage to be in the 2.0x to 2.5x range

    80% confidence
  • Excluding stranded costs, pro forma margin would be up 30 basis points year over year, supported by flow-through and manufacturing and material improvements, as well as faster growth in software and services

    80% confidence
  • 2027 DRAM negotiations are already underway and Aptiv expects increases to be higher than 2026 but below the 100% to 120% increases being discussed in the market, adding that the company has engaged OEM customers and is confident it can pass through higher costs

    80% confidence
  • Adjusted EBITDA and adjusted operating income margins were in line with the company's outlook, but pressured by foreign exchange and commodities, which amounted to a 160-basis-point headwind to margin in the quarter

    80% confidence
  • The outlook includes about $50 million in stranded costs and $35 million of engineering and go-to-market investments to support non-auto growth

    80% confidence
  • Inventory coverage has been increased to about 12 weeks to improve supply chain resiliency amid concerns about an industry-wide DRAM shortage

    80% confidence
  • Aptiv's purchase value for memory is roughly $175 million for 2026, mostly DRAM 3 and DRAM 4, with low double-digit price increases expected in 2026 due to inventory and longer-term supplier contracts

    80% confidence
  • The EDS business had a very good year in 2025, with solid revenue growth, EBITDA margin expansion, and strong bookings

    80% confidence
  • Aptiv delivered another solid quarter while navigating a shifting macro environment

    80% confidence
  • Excluding FX and commodities, fourth-quarter operating income margin would have been up 70 basis points versus the prior year, citing volume flow-through and performance improvements

    80% confidence
  • China revenue fell 5% attributed to unfavorable mix, though performance versus the market improved

    80% confidence
  • Full-year Intelligent Systems segment margins increased 30 basis points excluding FX, but fourth-quarter results were impacted by significant FX pressure, less fourth-quarter weighting of engineering credits than typical, and accelerated engineering investment related to robotics opportunities

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com
Aptiv Q4 Earnings Call Highlights — Source | Via News | Via News